China Medical System Holdings Limited (0867.HK)
HKD 8.21
(2.37%)
HKD 8.21
(2.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.3 Billion CNY | -28.19% |
| 2022 | 1.81 Billion CNY | 5.86% |
| 2021 | 1.71 Billion CNY | 185.31% |
| 2020 | 600.15 Million CNY | -15.92% |
| 2019 | 713.78 Million CNY | -51.28% |
| 2018 | 1.46 Billion CNY | -30.4% |
| 2017 | 2.1 Billion CNY | 30.55% |
| 2016 | 1.61 Billion CNY | 247.57% |
| 2015 | 463.9 Million CNY | -4.2% |
| 2014 | 484.24 Million CNY | 55.09% |
| 2013 | 312.22 Million CNY | -22.86% |
| 2012 | 404.75 Million CNY | 61.02% |
| 2011 | 251.36 Million CNY | 789.41% |
| 2010 | 28.26 Million CNY | -74.94% |
| 2009 | 112.77 Million CNY | 0.0% |
| 2008 | - CNY | 0.0% |
| 2007 | - CNY | -100.0% |
| 2006 | 29.15 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.1 Billion CNY | 3.19% |
| 2024 Q1 | 1.1 Billion CNY | -15.0% |
| 2023 Q4 | 1.3 Billion CNY | -0.14% |
| 2023 Q2 | 1.32 Billion CNY | 1.13% |
| 2023 FY | 1.3 Billion CNY | -28.19% |
| 2023 Q1 | 1.3 Billion CNY | -27.85% |
| 2023 Q3 | 1.3 Billion CNY | -1.43% |
| 2022 FY | 1.81 Billion CNY | 5.86% |
| 2022 Q4 | 1.81 Billion CNY | 0.88% |
| 2022 Q3 | 1.79 Billion CNY | -0.33% |
| 2022 Q2 | 1.8 Billion CNY | 0.75% |
| 2022 Q1 | 1.78 Billion CNY | 4.5% |
| 2021 Q3 | 1.69 Billion CNY | 54.77% |
| 2021 Q4 | 1.71 Billion CNY | 0.88% |
| 2021 Q2 | 1.09 Billion CNY | 0.09% |
| 2021 FY | 1.71 Billion CNY | 185.31% |
| 2021 Q1 | 1.09 Billion CNY | 82.57% |
| 2020 Q3 | 598.77 Million CNY | -14.68% |
| 2020 Q2 | 701.81 Million CNY | -0.1% |
| 2020 Q1 | 702.48 Million CNY | -1.58% |
| 2020 Q4 | 600.15 Million CNY | 0.23% |
| 2020 FY | 600.15 Million CNY | -15.92% |
| 2019 Q2 | 1.44 Billion CNY | 0.0% |
| 2019 Q1 | 1.44 Billion CNY | -1.5% |
| 2019 FY | 713.78 Million CNY | -51.28% |
| 2019 Q4 | 713.78 Million CNY | 1.31% |
| 2019 Q3 | 704.54 Million CNY | -51.18% |
| 2018 Q1 | 1.76 Billion CNY | -16.34% |
| 2018 Q2 | 1.76 Billion CNY | 0.0% |
| 2018 Q3 | 1.46 Billion CNY | -16.8% |
| 2018 Q4 | 1.46 Billion CNY | 0.0% |
| 2018 FY | 1.46 Billion CNY | -30.4% |
| 2017 Q1 | 3.16 Billion CNY | 96.35% |
| 2017 Q4 | 2.1 Billion CNY | 0.0% |
| 2017 Q3 | 2.1 Billion CNY | -33.51% |
| 2017 Q2 | 3.16 Billion CNY | 0.0% |
| 2017 FY | 2.1 Billion CNY | 30.55% |
| 2016 Q3 | 1.61 Billion CNY | -5.47% |
| 2016 Q2 | 1.7 Billion CNY | 0.0% |
| 2016 FY | 1.61 Billion CNY | 247.57% |
| 2016 Q1 | 1.7 Billion CNY | 267.7% |
| 2016 Q4 | 1.61 Billion CNY | 0.0% |
| 2015 Q4 | 463.9 Million CNY | 0.0% |
| 2015 FY | 463.9 Million CNY | -4.2% |
| 2015 Q3 | 463.9 Million CNY | -9.85% |
| 2015 Q2 | 514.58 Million CNY | 0.0% |
| 2015 Q1 | 514.58 Million CNY | 6.27% |
| 2014 FY | 484.24 Million CNY | 55.09% |
| 2014 Q4 | 484.24 Million CNY | 0.0% |
| 2014 Q3 | 484.24 Million CNY | 65.48% |
| 2014 Q2 | 292.62 Million CNY | 0.0% |
| 2014 Q1 | 292.62 Million CNY | -6.28% |
| 2013 Q4 | 312.22 Million CNY | -0.6% |
| 2013 FY | 312.22 Million CNY | -22.86% |
| 2013 Q1 | 500.49 Million CNY | 23.66% |
| 2013 Q2 | 496.38 Million CNY | -0.82% |
| 2013 Q3 | 314.12 Million CNY | -36.72% |
| 2012 Q2 | 562.19 Million CNY | 0.0% |
| 2012 Q4 | 404.75 Million CNY | 0.0% |
| 2012 Q3 | - CNY | -100.0% |
| 2012 FY | 404.75 Million CNY | 61.02% |
| 2012 Q1 | - CNY | -100.0% |
| 2011 FY | 251.36 Million CNY | 789.41% |
| 2011 Q4 | 251.36 Million CNY | 0.0% |
| 2011 Q2 | 179.23 Million CNY | 0.0% |
| 2010 Q2 | 111.3 Million CNY | 0.0% |
| 2010 FY | 28.26 Million CNY | -74.94% |
| 2010 Q4 | 28.26 Million CNY | 0.0% |
| 2009 Q4 | 112.77 Million CNY | 0.0% |
| 2009 FY | 112.77 Million CNY | 0.0% |
| 2008 FY | - CNY | 0.0% |
| 2007 FY | - CNY | -100.0% |
| 2006 FY | 29.15 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -19015.084% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 61.761% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -981.087% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -182.404% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -267197.125% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -537.669% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -342.734% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -289.948% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -206.457% |
| SSY Group Limited | 3.37 Billion HKD | 61.42% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -875.764% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | -73.709% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 98.484% |